# Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

> **NCT02739360** · PHASE4 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 3 (actual)

## Conditions studied

- Lymphoid Malignancies

## Interventions

- **DRUG:** Idelalisib

## Key facts

- **NCT ID:** NCT02739360
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-04
- **Primary completion:** 2017-12-28
- **Final completion:** 2017-12-28
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2020-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02739360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02739360, "Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02739360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*